ReviewFrontiers in bioengineering and biotechnology2021
Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.
Review in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Antiangiogenic therapy exerts antitumor effects by altering the tumor microenvironment: bibliometric analysis.Frontiers in immunology · 2024Pooled it
- From Breakthrough to Access: How Biotechnology and Artificial Intelligence are Reshaping the Scalability and Precision of Cancer Immunotherapy.Iranian journal of biotechnology · 2026Article
- ZBTB7B inhibits glioma tumorigenicity by upregulating GPR17 and CXCL10.Journal of molecular cell biology · 2026Article
- The "Cold Tumor" to "Hot Tumor" transformation strategy for triple-negative breast cancer: from mechanism to clinical translation.Molecular and cellular biochemistry · 2026Review
- Machine learning identifies a DNA repair-related risk model for bladder cancer and functionally characterizes ZWINT as a potential oncogenic factor.Translational andrology and urology · 2026Article
- Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).Journal of gynecologic oncology · 2026Article
- From cold to hot tumors: feasibility of applying therapeutic insights to TNBC.Discover oncology · 2025Review
- Bovine serum albumin nanoparticles encapsulating Dasatinib and Celecoxib for oral cancer: Preparation, characterization, and in-vitro evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Bioactive metallic nanoparticles for synergistic cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Covalent organic frameworks in cancer theranostics: advancing biomarker detection and tumor-targeted therapy.Archives of pharmacal research · 2025Review
- Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.World journal of surgical oncology · 2025Article
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- MRI guided copper deprivator activated immune responses and suppressed angiogenesis for enhanced antitumor immunotherapy.Theranostics · 2025Article
- Immunologic tumor microenvironment modulators for turning cold tumors hot.Cancer communications (London, England) · 2024Review
- Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy.International journal of nanomedicine · 2024Review
- Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2023Review
- Review
- Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.Cancer biology & medicine · 2023Review
- Mn-based cGAS-STING activation for tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnologies are rapidly increasing their role in immuno-oncology in line with the need for novel therapeutic strategies to treat patients unresponsive to chemotherapies and immunotherapies. The tumor immune microenvironment (TIME) has emerged as critical for tumor classification and patient stratification to design better treatments. Notably, the tumor infiltration of effector T cells plays a crucial role in antitumor responses and has been identified as the primary parameter to define hot, immunosuppressed, excluded, and cold tumors. Organic and inorganic nanoparticles (NPs) have been applied as carriers of new targeted therapies to turn cold or altered (i.e., immunosuppressed or excluded) tumors into more therapeutically responsive hot tumors. This mini-review discusses the significant advances in NP-based approaches to turn immunologically cold tumors into hot ones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.